Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1751 - 1775 of 2599 in total
AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8. It was investigated for the treatment of neuronal ceroid lipofuscinosis type 7.
Investigational
Matched Synonyms: … An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/ …
Matched Description: … It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human …
Investigational
Matched Synonyms: … 6-amino-9-(2',3'-dideoxy-.beta.-d-glycero-pentofuranosyl)purine ... 9-(2,3-dideoxy-.beta.-d-glycero-pentofuranosyl)-9h-purin-6-amine …
Matched Iupac: … [(2S,5R)-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methanol …
SP1049C is a novel anthracycline chemotherapeutic agent containing doxorubicin and two nonionic pluronic block copolymers. It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. Preliminary data, in its first clinically tested indication,...
Investigational
ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.
Investigational
Experimental
Matched Name: … 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE …
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
GP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).
Investigational
Kisspeptin-10 is under investigation in clinical trial NCT03771326 (KP-10 and Insulin Secretion in Men).
Investigational
Matched Synonyms: … Kisspeptin-10 (human) …
Matched Name: … Kisspeptin-10
Matched Description: … Kisspeptin-10 is under investigation in clinical trial NCT03771326 (KP-10 and Insulin Secretion in Men …
ZVS101e is a recombinant adeno-associated virus vector carrying human CYP4V2 gene.
Investigational
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as...
Experimental
Experimental
Matched Iupac: … 14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one …
ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells.
Investigational
Giroctocogene fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia a Adults).
Investigational
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
Experimental
Matched Synonyms: … 2-(2-Hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine …
Matched Name: … 2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol …
Matched Iupac: … 2-({6-[(3-chlorophenyl)amino]-9-(propan-2-yl)-9H-purin-2-yl}amino)ethan-1-ol …
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3,5,7,9,11,13,15,17,19,21(24)-decaen-4-yl]propanoic acid ... -9,10,14,15-tetraethenyl-5,19-dimethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoic acid ... carboxyethyl)-5,10,15,20-tetramethyl-2,22,23,25-tetraaza-1-cobaltaoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
Investigational
Matched Synonyms: … Cholest-5-ene-3,7-diol, 3-(9z)-9-octadecenoate, (3.beta.,7.beta.)- …
Matched Iupac: … yl]-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl (9Z)-octadec-9- …
Experimental
Matched Iupac: … {1,10}.0^{2,8}]heptadecane-9-carboxylic acid ... 1R,2R,5R,8R,9S,10R,11S,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.1^{5,8}.0^ …
AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Investigational
Investigational
Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Experimental
Matched Synonyms: … 4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol ... 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol …
Matched Iupac: … 2-{4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]piperazin-1-yl}ethan-1-ol …
Investigational
Matched Synonyms: … 4,5,9-trithiadodeca-1,6,11-triene 9-oxide ... (E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene) …
BCX10013 is a small molecule inhibitor of human complement factor D.
Investigational
Displaying drugs 1751 - 1775 of 2599 in total